DE602005026984D1 - Chinolin-derivate zur behandlung von latenter tuberkulose - Google Patents

Chinolin-derivate zur behandlung von latenter tuberkulose

Info

Publication number
DE602005026984D1
DE602005026984D1 DE602005026984T DE602005026984T DE602005026984D1 DE 602005026984 D1 DE602005026984 D1 DE 602005026984D1 DE 602005026984 T DE602005026984 T DE 602005026984T DE 602005026984 T DE602005026984 T DE 602005026984T DE 602005026984 D1 DE602005026984 D1 DE 602005026984D1
Authority
DE
Germany
Prior art keywords
latente
chinolin
tuberculosis
derivatives
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005026984T
Other languages
English (en)
Inventor
Koenraad Jozef Lodewijk Marcel Andries
Anil Koul
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35717702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602005026984(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE602005026984D1 publication Critical patent/DE602005026984D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
DE602005026984T 2004-12-24 2005-12-08 Chinolin-derivate zur behandlung von latenter tuberkulose Active DE602005026984D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078529 2004-12-24
EP05105008 2005-06-08
PCT/EP2005/056594 WO2006067048A1 (en) 2004-12-24 2005-12-08 Quinoline derivatives for the treatment of latent tuberculosis

Publications (1)

Publication Number Publication Date
DE602005026984D1 true DE602005026984D1 (de) 2011-04-28

Family

ID=35717702

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005026984T Active DE602005026984D1 (de) 2004-12-24 2005-12-08 Chinolin-derivate zur behandlung von latenter tuberkulose

Country Status (31)

Country Link
US (1) US20060142279A1 (de)
EP (1) EP1830850B1 (de)
CN (1) CN103142595B (de)
AP (1) AP2327A (de)
AR (1) AR051790A1 (de)
AT (1) ATE501721T1 (de)
AU (1) AU2005242138B2 (de)
BR (1) BRPI0506400B8 (de)
CA (1) CA2529265C (de)
CR (1) CR9267A (de)
CY (1) CY1112247T1 (de)
DE (1) DE602005026984D1 (de)
DK (1) DK1830850T3 (de)
EE (1) EE05394B1 (de)
HK (1) HK1186125A1 (de)
HR (1) HRP20110392T1 (de)
IL (1) IL184123A (de)
LV (1) LV13469B (de)
ME (1) ME01207B (de)
MY (1) MY145845A (de)
NI (1) NI200700146A (de)
NO (1) NO340376B1 (de)
NZ (1) NZ555460A (de)
PA (1) PA8654801A1 (de)
PL (1) PL1830850T3 (de)
PT (1) PT1830850E (de)
RS (1) RS51730B (de)
SI (1) SI1830850T1 (de)
TR (1) TR200504892A1 (de)
TW (1) TWI404535B (de)
WO (1) WO2006067048A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1527050B1 (de) * 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Chinolinderivate und deren verwendung als mycobakterielle inhibitoren
CN101252927B (zh) * 2005-06-28 2014-01-01 詹森药业有限公司 作为抗菌剂的喹啉衍生物
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
CA2711912A1 (en) * 2008-01-14 2009-07-23 Jyoti Chattopadhyaya Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivates as anti-mycobacterial agents
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
WO2010083436A1 (en) 2009-01-15 2010-07-22 Rutgers, The State University Of New Jersey Benzo [c] phenanthridines as antimicrobial agents
WO2010127307A1 (en) 2009-04-30 2010-11-04 Rutgers, The State University Of New Jersey Antimicrobial agents
US8933096B2 (en) 2010-06-09 2015-01-13 Rugers, The State University of New Jersey Antimicrobial agents
US9102617B2 (en) 2010-06-25 2015-08-11 Rutgers, The State University Of New Jersey Antimicrobial agents
WO2013106756A2 (en) 2012-01-13 2013-07-18 Rutgers, The State University Of New Jersey Antimicrobial agents
AU2013235038A1 (en) 2012-03-21 2014-10-09 Malvika Kaul Antimicrobial agents
CA2869718C (en) 2012-04-27 2021-05-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9617244B2 (en) 2012-04-27 2017-04-11 Janssen Pharmaceutica Nv Antibacterial quinoline derivatives
US9458150B2 (en) 2013-11-08 2016-10-04 Rutgers, The State University Of New Jersey Antimicrobial agents
IL253626B1 (en) 2015-01-27 2024-04-01 Janssen Pharmaceutica Nv dispersible preparations
EP3419967A4 (de) 2016-02-25 2019-10-16 Taxis Pharmaceuticals, Inc. Synthetische verfahren und zwischenprodukte
US10508097B2 (en) * 2016-03-07 2019-12-17 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
RU2629369C1 (ru) * 2016-10-05 2017-08-29 Федеральное Государственное Унитарное Предприятие "Государственный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Химических Реактивов И Особо Чистых Химических Веществ" Четвертичные аммонийные производные 2-аминотиофен-3-карбоксилатов, обладающие противотуберкулезной активностью
WO2018183917A1 (en) 2017-03-30 2018-10-04 Taxis Pharmaceuticals, Inc. Synthetic processes and synthetic intermediates
DK3651736T3 (da) 2017-07-14 2021-09-27 Janssen Pharmaceutica Nv Langtidsvirkende formuleringer
RU2661151C1 (ru) * 2017-12-14 2018-07-12 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Селективные ингибиторы глицеральдегид-3-фосфатдегидрогеназы микобактерий
JP2022516671A (ja) 2019-01-09 2022-03-01 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性抗酸菌症の処置における組合せ
WO2022008645A1 (en) 2020-07-09 2022-01-13 Janssen Pharmaceutica Nv Long-acting formulations
KR20230038521A (ko) 2020-07-09 2023-03-20 얀센 파마슈티카 엔.브이. 장기 작용 제형
JP2023549605A (ja) 2020-11-12 2023-11-28 ヤンセン ファーマシューティカ エヌ．ベー． 非結核性マイコバクテリア疾患の治療におけるベダキリン、エタンブトール、及びマクロライドの組合せ
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR038536A1 (es) * 2002-02-25 2005-01-19 Upjohn Co N-aril-2-oxazolidinona-5- carboxamidas y sus derivados
EP1527050B1 (de) * 2002-07-25 2010-04-07 Janssen Pharmaceutica N.V. Chinolinderivate und deren verwendung als mycobakterielle inhibitoren

Also Published As

Publication number Publication date
CA2529265A1 (en) 2006-06-24
EE200500033A (et) 2006-08-15
NZ555460A (en) 2008-11-28
PL1830850T3 (pl) 2011-07-29
CN103142595A (zh) 2013-06-12
HK1186125A1 (en) 2014-03-07
PA8654801A1 (es) 2006-08-03
HRP20110392T1 (hr) 2011-06-30
TW200637551A (en) 2006-11-01
AR051790A1 (es) 2007-02-07
EP1830850B1 (de) 2011-03-16
LV13469B (en) 2007-01-20
EP1830850A1 (de) 2007-09-12
AU2005242138A1 (en) 2006-07-13
RS51730B (en) 2011-10-31
NO340376B1 (no) 2017-04-10
AU2005242138B2 (en) 2011-05-26
BRPI0506400B8 (pt) 2021-05-25
MY145845A (en) 2012-04-30
CR9267A (es) 2008-09-09
CA2529265C (en) 2014-02-11
IL184123A0 (en) 2008-12-29
DK1830850T3 (da) 2011-06-14
BRPI0506400B1 (pt) 2021-04-06
US20060142279A1 (en) 2006-06-29
SI1830850T1 (sl) 2011-07-29
WO2006067048A1 (en) 2006-06-29
AP2327A (en) 2011-11-25
AP2007004054A0 (en) 2007-06-30
CN103142595B (zh) 2015-05-06
CY1112247T1 (el) 2015-12-09
BRPI0506400A8 (pt) 2017-09-12
EE05394B1 (et) 2011-04-15
NO20073823L (no) 2007-07-23
ATE501721T1 (de) 2011-04-15
BRPI0506400A (pt) 2006-08-29
TR200504892A1 (tr) 2010-04-21
TWI404535B (zh) 2013-08-11
PT1830850E (pt) 2011-05-31
IL184123A (en) 2011-10-31
ME01207B (me) 2013-03-20
NI200700146A (es) 2019-05-10

Similar Documents

Publication Publication Date Title
DE602005026984D1 (de) Chinolin-derivate zur behandlung von latenter tuberkulose
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
DE602005017503D1 (de) Biphenyloxyessigsäure - derivate zur behandlung von atemwegserkränkungen
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
DE602005019899D1 (de) System zur behandlung von ischämischem schlaganfall
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE534633T1 (de) Indazolderivate zur behandlung von hsp90- induzierten krankheiten
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
ATE526970T1 (de) Behandlung von mastitis
ATE525355T1 (de) 1-ä(4-äbenzoyl(methyl)aminoü-3- (phenyl)butylüazetidinderivate zur behandlung von gastrointestinalen erkrankungen 1
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
ATE457725T1 (de) Kynurenine 3-hydroxylase inhibitoren zur behandlung von diabetes
ATE448228T1 (de) Pyrrolopyrimidinderivate zur behandlung proliferativer krankheiten